Childhood Kidney Diseases

Korean Society of Pediatric Nephrology (대한소아신장학회)
권호 표지
DOI QR코드

DOI QR Code

Anemia in children with chronic kidney disease

  • Min Ji Park (Department of Pediatrics, Kyungpook National University Hospital, School of Medicine, Kyungpook National University) ;
  • Min Hyun Cho (Department of Pediatrics, Kyungpook National University Hospital, School of Medicine, Kyungpook National University)
  • Received : 2023.09.26
  • Accepted : 2023.10.22
  • Published : 2023.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Chronic kidney disease (CKD) causes numerous changes that destabilize homeostasis, of which anemia is one of its important complications. Anemia significantly reduces the quality of life in children with CKD and plays a crucial role in the progression of cardiovascular disease such as left ventricular hypertrophy, a major cause of mortality in those with advanced CKD. The treatment of anemia is a pivotal factor in reducing morbidity and mortality rates in children with CKD, representing one of the methods for enhancing patients' quality of life.

Keywords

References

  1. Bright R. Cases and observations illustrative of renal disease, accompanied with the secretion of albuminous urine. Med Chir Rev 1836;25:23-35.
  2. Cameron JS. Sir Robert Christison (1797-1882): the man, his times, and his contributions to nephrology. J R Coll Physicians Edinb 2007;37:155-72.
  3. Fadrowski JJ, Pierce CB, Cole SR, Moxey-Mims M, Warady BA, Furth SL. Hemoglobin decline in children with chronic kidney disease: baseline results from the chronic kidney disease in children prospective cohort study. Clin J Am Soc Nephrol 2008;3:457-62. https://doi.org/10.2215/CJN.03020707
  4. Atkinson MA, Martz K, Warady BA, Neu AM. Risk for anemia in pediatric chronic kidney disease patients: a report of NAPRTCS. Pediatr Nephrol 2010;25:1699-706. https://doi.org/10.1007/s00467-010-1538-6
  5. KDOQI; National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 2006;47:S11-145. https://doi.org/10.1053/j.ajkd.2006.03.011
  6. Gerson A, Hwang W, Fiorenza J, Barth K, Kaskel F, Weiss L, et al. Anemia and health-related quality of life in adolescents with chronic kidney disease. Am J Kidney Dis 2004;44:1017-23. https://doi.org/10.1053/j.ajkd.2004.08.024
  7. Baek HS, Kang HG, Choi HJ, Cheong HI, Ha IS, Han KH, et al. Health-related quality of life of children with pre-dialysis chronic kidney disease. Pediatr Nephrol 2017;32:2097-105. https://doi.org/10.1007/s00467-017-3721-5
  8. Matteucci MC, Wuhl E, Picca S, Mastrostefano A, Rinelli G, Romano C, et al. Left ventricular geometry in children with mild to moderate chronic renal insufficiency. J Am Soc Nephrol 2006;17:218-26. https://doi.org/10.1681/ASN.2005030276
  9. Mitsnefes MM. Cardiovascular disease in children with chronic kidney disease. J Am Soc Nephrol 2012;23:578-85. https://doi.org/10.1681/ASN.2011111115
  10. Staples AO, Wong CS, Smith JM, Gipson DS, Filler G, Warady BA, et al. Anemia and risk of hospitalization in pediatric chronic kidney disease. Clin J Am Soc Nephrol 2009;4:48-56. https://doi.org/10.2215/CJN.05301107
  11. Amaral S, Hwang W, Fivush B, Neu A, Frankenfield D, Furth S. Association of mortality and hospitalization with achievement of adult hemoglobin targets in adolescents maintained on hemodialysis. J Am Soc Nephrol 2006;17:2878-85. https://doi.org/10.1681/ASN.2005111215
  12. Warady BA, Ho M. Morbidity and mortality in children with anemia at initiation of dialysis. Pediatr Nephrol 2003;18:1055-62. https://doi.org/10.1007/s00467-003-1214-1
  13. Jacobson LO, Goldwasser E, Fried W, Plzak L. Role of the kidney in erythropoiesis. Nature 1957;179:633-4. https://doi.org/10.1038/179633a0
  14. Adamson JW, Eschbach J, Finch CA. The kidney and erythropoiesis. Am J Med 1968;44:725-33. https://doi.org/10.1016/0002-9343(68)90254-4
  15. Babitt JL, Lin HY. Mechanisms of anemia in CKD. J Am Soc Nephrol 2012;23:1631-4. https://doi.org/10.1681/ASN.2011111078
  16. Atkinson MA, Warady BA. Anemia in chronic kidney disease. Pediatr Nephrol 2018;33:227-38.
  17. Atkinson MA, Furth SL. Anemia in children with chronic kidney disease. Nat Rev Nephrol 2011;7:635-41. https://doi.org/10.1038/nrneph.2011.115
  18. Koshy SM, Geary DF. Anemia in children with chronic kidney disease. Pediatr Nephrol 2008;23:209-19. https://doi.org/10.1007/s00467-006-0381-2
  19. Babitt JL, Lin HY. Molecular mechanisms of hepcidin regulation: implications for the anemia of CKD. Am J Kidney Dis 2010;55:726-41. https://doi.org/10.1053/j.ajkd.2009.12.030
  20. Zaritsky J, Young B, Wang HJ, Westerman M, Olbina G, Nemeth E, et al. Hepcidin: a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol 2009;4:1051-6. https://doi.org/10.2215/CJN.05931108
  21. Ganz T, Nemeth E. Iron balance and the role of hepcidin in chronic kidney disease. Semin Nephrol 2016;36:87-93. https://doi.org/10.1016/j.semnephrol.2016.02.001
  22. Atkinson MA, Kim JY, Roy CN, Warady BA, White CT, Furth SL. Hepcidin and risk of anemia in CKD: a cross-sectional and longitudinal analysis in the CKiD cohort. Pediatr Nephrol 2015;30:635-43. https://doi.org/10.1007/s00467-014-2991-4
  23. Nemeth E, Ganz T. Hepcidin and iron in health and disease. Annu Rev Med 2023;74:261-77. https://doi.org/10.1146/annurev-med-043021-032816
  24. Atkinson MA, Pierce CB, Zack RM, Barletta GM, Yadin O, Mentser M, et al. Hemoglobin differences by race in children with CKD. Am J Kidney Dis 2010;55:1009-17. https://doi.org/10.1053/j.ajkd.2009.12.040
  25. Hollowell JG, van Assendelft OW, Gunter EW, Lewis BG, Najjar M, Pfeiffer C, et al. Hematological and iron-related analytes: reference data for persons aged 1 year and over: United States, 1988-94. Vital Health Stat 11 2005;(247):1-156.
  26. National Kidney Foundation Anemia Working Group. IV. NKF-K/DOQI clinical practice guidelines for anemia of chronic kidney disease: update 2000. Am J Kidney Dis 2001;37(1 Suppl 1):S182-238. https://doi.org/10.1016/S0272-6386(01)70008-X
  27. Filler G, Mylrea K, Feber J, Wong H. How to define anemia in children with chronic kidney disease? Pediatr Nephrol 2007;22:702-7. https://doi.org/10.1007/s00467-006-0397-7
  28. McMurray J, Parfrey P, Adamson JW, Aljama P, Berns JS, Bohlius J, et al. Kidney Disease: Improving Global Outcomes (KDIGO) anemia work group: KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl 2012;279:702-335.
  29. Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease: results of a phase III multicenter clinical trial. Ann Intern Med 1989;111:992-1000. https://doi.org/10.7326/0003-4819-111-12-992
  30. Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. BMJ 1990;300:573-8. https://doi.org/10.1136/bmj.300.6724.573
  31. Nissenson AR, Swan SK, Lindberg JS, Soroka SD, Beatey R, Wang C, et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis 2002;40:110-8. https://doi.org/10.1053/ajkd.2002.33919
  32. Levin NW, Fishbane S, Canedo FV, Zeig S, Nassar GM, Moran JE, et al. Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA). Lancet 2007;370:1415-21. https://doi.org/10.1016/S0140-6736(07)61599-2
  33. Krapf R, Hulter HN. Arterial hypertension induced by erythropoietin and erythropoiesis-stimulating agents (ESA). Clin J Am Soc Nephrol 2009;4:470-80. https://doi.org/10.2215/CJN.05040908
  34. McCullough PA, Barnhart HX, Inrig JK, Reddan D, Sapp S, Patel UD, et al. Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease. Am J Nephrol 2013;37:549-58. https://doi.org/10.1159/000351175
  35. Smith KJ, Bleyer AJ, Little WC, Sane DC. The cardiovascular effects of erythropoietin. Cardiovasc Res 2003;59:538-48. https://doi.org/10.1016/S0008-6363(03)00468-1
  36. Horl WH. Anaemia management and mortality risk in chronic kidney disease. Nat Rev Nephrol 2013;9:291-301. https://doi.org/10.1038/nrneph.2013.21
  37. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998;339:584-90. https://doi.org/10.1056/NEJM199808273390903
  38. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085-98. https://doi.org/10.1056/NEJMoa065485
  39. Parfrey PS, Foley RN, Wittreich BH, Sullivan DJ, Zagari MJ, Frei D. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 2005;16:2180-9. https://doi.org/10.1681/ASN.2004121039
  40. Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Tonelli M, Garg AX, et al. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med 2010;153:23-33. https://doi.org/10.7326/0003-4819-153-1-201007060-00252
  41. Coyne DW. The health-related quality of life was not improved by targeting higher hemoglobin in the Normal Hematocrit Trial. Kidney Int 2012;82:235-41. https://doi.org/10.1038/ki.2012.76
  42. Johnson DW, Pollock CA, Macdougall IC. Erythropoiesis-stimulating agent hyporesponsiveness. Nephrology (Carlton) 2007;12:321-30. https://doi.org/10.1111/j.1440-1797.2007.00810.x
  43. Kalantar-Zadeh K, Lee GH, Miller JE, Streja E, Jing J, Robertson JA, et al. Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients. Am J Kidney Dis 2009;53:823-34. https://doi.org/10.1053/j.ajkd.2008.12.040
  44. Seeherunvong W, Rubio L, Abitbol CL, Montane B, Strauss J, Diaz R, et al. Identification of poor responders to erythropoietin among children undergoing hemodialysis. J Pediatr 2001;138:710-4. https://doi.org/10.1067/mpd.2001.112246
  45. Macdougall IC, Bircher AJ, Eckardt KU, Obrador GT, Pollock CA, Stenvinkel P, et al. Iron management in chronic kidney disease: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. Kidney Int 2016;89:28-39. https://doi.org/10.1016/j.kint.2015.10.002
  46. Gillespie RS, Wolf FM. Intravenous iron therapy in pediatric hemodialysis patients: a meta-analysis. Pediatr Nephrol 2004;19:662-6. https://doi.org/10.1007/s00467-004-1421-4
  47. Morgan HE, Gautam M, Geary DF. Maintenance intravenous iron therapy in pediatric hemodialysis patients. Pediatr Nephrol 2001;16:779-83. https://doi.org/10.1007/s004670100645
  48. Neu AM, Ho PL, McDonald RA, Warady BA. Chronic dialysis in children and adolescents. The 2001 NAPRTCS Annual Report. Pediatr Nephrol 2002;17:656-63.
  49. Warady BA, Kausz A, Lerner G, Brewer ED, Chadha V, Brugnara C, et al. Iron therapy in the pediatric hemodialysis population. Pediatr Nephrol 2004;19:655-61.
  50. Schroder CH; European Pediatric Peritoneal Dialysis Working Group. The management of anemia in pediatric peritoneal dialysis patients. Guidelines by an ad hoc European committee. Pediatr Nephrol 2003;18:805-9.
  51. Van Damme-Lombaerts R, Herman J. Erythropoietin treatment in children with renal failure. Pediatr Nephrol 1999;13:148-52. https://doi.org/10.1007/s004670050584
  52. Bothwell TH, Pirzio-Biroli G, Finch CA. Iron absorption. I. Factors influencing absorption. J Lab Clin Med 1958;51:24-36.
  53. Morgan HE, Holt RC, Jones CA, Judd BA. Intravenous iron treatment in paediatric chronic kidney disease patients not on erythropoietin. Pediatr Nephrol 2007;22:1963-5. https://doi.org/10.1007/s00467-007-0499-x
  54. Yorgin PD, Belson A, Sarwal M, Alexander SR. Sodium ferric gluconate therapy in renal transplant and renal failure patients. Pediatr Nephrol 2000;15:171-5. https://doi.org/10.1007/s004670000453
  55. Horl WH. Iron therapy for renal anemia: how much needed, how much harmful? Pediatr Nephrol 2007;22:480-9. https://doi.org/10.1007/s00467-006-0405-y
  56. Chandler G, Harchowal J, Macdougall IC. Intravenous iron sucrose: establishing a safe dose. Am J Kidney Dis 2001;38:988-91. https://doi.org/10.1053/ajkd.2001.28587
  57. Haase VH. HIF-prolyl hydroxylases as therapeutic targets in erythropoiesis and iron metabolism. Hemodial Int 2017;21 Suppl 1(Suppl 1):S110-24. https://doi.org/10.1111/hdi.12567
  58. Haase VH. Hypoxia-inducible factor-prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease. Kidney Int Suppl (2011) 2021;11:8-25. https://doi.org/10.1016/j.kisu.2020.12.002
  59. Locatelli F, Fishbane S, Block GA, Macdougall IC. Targeting hypoxia-inducible factors for the treatment of anemia in chronic kidney disease patients. Am J Nephrol 2017;45:187-99. https://doi.org/10.1159/000455166
  60. Singh AK, Carroll K, Perkovic V, Solomon S, Jha V, Johansen KL, et al. Daprodustat for the treatment of anemia in patients undergoing dialysis. N Engl J Med 2021;385:2325-35. https://doi.org/10.1056/NEJMoa2113379
  61. Akizawa T, Nangaku M, Yonekawa T, Okuda N, Kawamatsu S, Onoue T, et al. Efficacy and safety of daprodustat compared with darbepoetin alfa in Japanese hemodialysis patients with anemia: a randomized, double-blind, phase 3 trial. Clin J Am Soc Nephrol 2020;15:1155-65. https://doi.org/10.2215/CJN.16011219
  62. Singh AK, Carroll K, McMurray JJV, Solomon S, Jha V, Johansen KL, et al. Daprodustat for the treatment of anemia in patients not undergoing dialysis. N Engl J Med 2021;385:2313-24. https://doi.org/10.1056/NEJMoa2113380
  63. Zheng Q, Yang H, Sun L, Wei R, Fu X, Wang Y, et al. Efficacy and safety of HIF prolyl-hydroxylase inhibitor vs epoetin and darbepoetin for anemia in chronic kidney disease patients not undergoing dialysis: a network meta-analysis. Pharmacol Res 2020;159:105020.
  64. Hiemstra T, Vick JG, Roberts JC. WCN23-0672 Daprodustat for treatment of anemia of CKD in pediatric patients: protocol for the ASCEND-P trial within a cohort. Kidney Int Rep 2023;8(3 Suppl):S150-1. https://doi.org/10.1016/j.ekir.2023.02.337
  65. Shah HH, Fishbane S. Anemia and its treatment in patients with end-stage kidney disease. In: Nissenson AR, Fine RN, Mehrotra R, Zaritsky J, editors. Handbook of dialysis therapy. Elsevier; 2023. p.341-50.
  66. Niaudet P, Dudley J, Charbit M, Gagnadoux MF, Macleay K, Broyer M. Pretransplant blood transfusions with cyclosporine in pediatric renal transplantation. Pediatr Nephrol 2000;14:451-6.  https://doi.org/10.1007/s004670050791